08158.HK
China Regenerative Medicine International Limited
HKSE · Healthcare · Biotechnology · HK
HKD 0.25
−0.41%Year over year
Reported trailing growth
- Revenue
- +84.2%
- EBITDA
- +287.3%
- EBIT
- +418.7%
- EPS
- +439.5%
- Free cash flow
- +560.5%
- Operating cash flow
- +423.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +20.2%
- EBITDA
- -5.9%
- EBIT
- +10.1%
- Net income
- +82.1%
- EPS
- +78.2%
- Free cash flow
- -18.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026